SG11201805645QA - Lsd1 inhibitors - Google Patents
Lsd1 inhibitorsInfo
- Publication number
- SG11201805645QA SG11201805645QA SG11201805645QA SG11201805645QA SG11201805645QA SG 11201805645Q A SG11201805645Q A SG 11201805645QA SG 11201805645Q A SG11201805645Q A SG 11201805645QA SG 11201805645Q A SG11201805645Q A SG 11201805645QA SG 11201805645Q A SG11201805645Q A SG 11201805645QA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- pct
- compounds
- san diego
- present
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D211/74—Oxygen atoms
- C07D211/76—Oxygen atoms attached in position 2 or 6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
- C07D211/86—Oxygen atoms
- C07D211/88—Oxygen atoms attached in positions 2 and 6, e.g. glutarimide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/22—Bridged ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
- C07D265/06—1,3-Oxazines; Hydrogenated 1,3-oxazines not condensed with other rings
- C07D265/08—1,3-Oxazines; Hydrogenated 1,3-oxazines not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D265/10—1,3-Oxazines; Hydrogenated 1,3-oxazines not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with oxygen atoms directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 6 July 2017 (06.07.2017) WIPO I PCT (10) International Publication Number WO 2017/116558 Al 11111111111111011101111111111101011111011101110111111111111111111110111111111110111111 (74) Agent: GREENFIELD, Michael, S.; McDonnell Boehnen Hulbert & Berghoff LLP, 300 South Wacker Drive, Suite 3100, Chicago, IL 60606 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (51) International Patent Classification: CO7D 205/04 (2006.01) A61K 31/4468 (2006.01) CO7D 265/10 (2006.01) A61K 31/445 (2006.01) C07D 211/58 (2006.01) A61P 35/00 (2006.01) C07D 213/64 (2006.01) (21) International Application Number: PCT/US2016/060379 (22) International Filing Date: 3 November 2016 (03.11.2016) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/272,082 29 December 2015 (29.12.2015) US 62/295,369 15 February 2016 (15.02.2016) US (84) (71) Applicant: MIRATI THERAPEUTICS, INC. [US/US]; 9393 Towne Centre Drive, Suite 200, San Diego, CA 92121 (US). (72) Inventors: MARX, Matthew, Arnold; 10231 Lone Dove Street, San Diego, CA 92127 (US). VAISBURG, Arkadii; 10 Riverwood Grove, Kirkland, QC H9J 2X2 (CA). CHRISTENSEN, James, Gail; 4276 Kerwood Court, San Diego, CA 92130 (US). GALEMMO, Robert, Anthony, Jr.; 24 Whaleship Plaza, San Francisco, CA 94111 (US). Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) W O 20 17 / 11655 8 Al (54) Title: LSD1 INHIBITORS (57) : The present invention relates to compounds that inhibit LSD1 activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharma- ceutical compositions of the present invention.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562272082P | 2015-12-29 | 2015-12-29 | |
US201662295369P | 2016-02-15 | 2016-02-15 | |
PCT/US2016/060379 WO2017116558A1 (en) | 2015-12-29 | 2016-11-03 | Lsd1 inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201805645QA true SG11201805645QA (en) | 2018-07-30 |
Family
ID=57472003
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201805645QA SG11201805645QA (en) | 2015-12-29 | 2016-11-03 | Lsd1 inhibitors |
Country Status (11)
Country | Link |
---|---|
US (2) | US9809541B2 (en) |
EP (1) | EP3397616B1 (en) |
JP (1) | JP6916795B2 (en) |
KR (1) | KR20180117602A (en) |
CN (1) | CN108884029B (en) |
AU (1) | AU2016382463B2 (en) |
CA (1) | CA3009805C (en) |
IL (1) | IL260217B (en) |
MX (1) | MX2018008052A (en) |
SG (1) | SG11201805645QA (en) |
WO (1) | WO2017116558A1 (en) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ716427A (en) | 2013-08-06 | 2021-07-30 | Imago Biosciences Inc | Kdm1a inhibitors for the treatment of disease |
CN106488915B (en) | 2014-02-13 | 2020-10-02 | 因赛特公司 | Cyclopropylamines as LSD1 inhibitors |
EP3626713B1 (en) | 2014-02-13 | 2021-09-29 | Incyte Corporation | Cyclopropylamines for use as lsd1 inhibitors |
US9695167B2 (en) | 2014-07-10 | 2017-07-04 | Incyte Corporation | Substituted triazolo[1,5-a]pyridines and triazolo[1,5-a]pyrazines as LSD1 inhibitors |
WO2016130952A1 (en) | 2015-02-12 | 2016-08-18 | Imago Biosciences, Inc. | Kdm1a inhibitors for the treatment of disease |
AU2016243939B2 (en) | 2015-04-03 | 2020-09-03 | Incyte Holdings Corporation | Heterocyclic compounds as LSD1 inhibitors |
EA035534B1 (en) | 2015-08-12 | 2020-06-30 | Инсайт Корпорейшн | Salts of an lsd1 inhibitor |
WO2017079476A1 (en) * | 2015-11-05 | 2017-05-11 | Mirati Therapeutics, Inc. | Lsd1 inhibitors |
AU2017263361B2 (en) * | 2016-05-09 | 2021-08-05 | Jubilant Epicore LLC | Cyclopropyl-amide compounds as dual LSD1/HDAC inhibitors |
US11390590B2 (en) | 2016-08-16 | 2022-07-19 | Imago Biosciences, Inc. | Methods and processes for the preparation of KDM1A inhibitors |
US20190256930A1 (en) | 2016-11-03 | 2019-08-22 | Oryzon Genomics, S.A. | Biomarkers for determining responsiveness to lsd1 inhibitors |
JP7082806B2 (en) * | 2017-07-07 | 2022-06-09 | 学校法人自治医科大学 | Teratoma formation inhibitor from pluripotent stem cells and its uses |
JP2020529995A (en) | 2017-08-03 | 2020-10-15 | オリゾン ジェノミックス ソシエダッド アノニマ | How to treat behavioral changes |
US11685782B2 (en) | 2017-10-23 | 2023-06-27 | Children's Medical Center Corporation | Methods of treating cancer using LSD1 inhibitors in combination with immunotherapy |
JP7450559B2 (en) * | 2018-05-11 | 2024-03-15 | イマーゴ バイオサイエンシーズ インコーポレイテッド | KDM1A inhibitors for the treatment of diseases |
WO2020047198A1 (en) | 2018-08-31 | 2020-03-05 | Incyte Corporation | Salts of an lsd1 inhibitor and processes for preparing the same |
EP3941465A1 (en) | 2019-03-20 | 2022-01-26 | Oryzon Genomics, S.A. | Methods of treating attention deficit hyperactivity disorder using kdm1a inhibitors such as the compound vafidemstat |
KR20210141933A (en) | 2019-03-20 | 2021-11-23 | 오리존 지노믹스 에스.에이. | How to treat borderline personality disorder |
JP2022546908A (en) | 2019-07-05 | 2022-11-10 | オリゾン・ゲノミクス・ソシエダッド・アノニマ | Biomarkers and methods for personalized treatment of small cell lung cancer using KDM1A inhibitors |
KR20230167102A (en) | 2021-04-08 | 2023-12-07 | 오리존 지노믹스 에스.에이. | Combination of LSD1 inhibitors for the treatment of myeloid cancer |
GB202115017D0 (en) | 2021-10-20 | 2021-12-01 | Univ London Queen Mary | Sequential treatments and biomarkers to reverse resistance to kinase inhibitors |
WO2023067058A1 (en) | 2021-10-20 | 2023-04-27 | Queen Mary University Of London | Sequential treatments and biomarkers to reverse resistance to kinase inhibitors |
WO2023217784A1 (en) | 2022-05-09 | 2023-11-16 | Oryzon Genomics, S.A. | Methods of treating nf1-mutant tumors using lsd1 inhibitors |
WO2023217758A1 (en) | 2022-05-09 | 2023-11-16 | Oryzon Genomics, S.A. | Methods of treating malignant peripheral nerve sheath tumor (mpnst) using lsd1 inhibitors |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7244751B2 (en) | 2003-02-14 | 2007-07-17 | Shenzhen Chipscreen Biosciences Ltd. | Histone deacetylase inhibitors of novel benzamide derivatives with potent differentiation and anti-proliferation activity |
CA2662937A1 (en) | 2006-09-11 | 2008-03-20 | Curis, Inc. | Multi-functional small molecules as anti-proliferative agents |
WO2010043721A1 (en) | 2008-10-17 | 2010-04-22 | Oryzon Genomics, S.A. | Oxidase inhibitors and their use |
WO2010084160A1 (en) * | 2009-01-21 | 2010-07-29 | Oryzon Genomics S.A. | Phenylcyclopropylamine derivatives and their medical use |
CA2812683C (en) | 2009-09-25 | 2017-10-10 | Oryzon Genomics S.A. | Lysine specific demethylase-1 inhibitors and their use |
EP2486002B1 (en) | 2009-10-09 | 2019-03-27 | Oryzon Genomics, S.A. | Substituted heteroaryl- and aryl- cyclopropylamine acetamides and their use |
BR112012026694A2 (en) | 2010-04-19 | 2016-07-12 | Oryzon Genomics Sa | lysine 1-specific demethylase inhibitors and their use |
SI2598482T1 (en) | 2010-07-29 | 2018-09-28 | Oryzon Genomics, S.A. | Arylcyclopropylamine based demethylase inhibitors of lsd1 and their medical use |
US20130303545A1 (en) | 2010-09-30 | 2013-11-14 | Tamara Maes | Cyclopropylamine derivatives useful as lsd1 inhibitors |
WO2012045883A1 (en) | 2010-10-08 | 2012-04-12 | Oryzon Genomics S.A. | Cyclopropylamine inhibitors of oxidases |
WO2012107499A1 (en) | 2011-02-08 | 2012-08-16 | Oryzon Genomics S.A. | Lysine demethylase inhibitors for myeloproliferative or lymphoproliferative diseases or disorders |
SG193241A1 (en) | 2011-03-25 | 2013-10-30 | Glaxosmithkline Ip No 2 Ltd | Cyclopropylamines as lsd1 inhibitors |
CA2831334A1 (en) | 2011-04-08 | 2012-10-11 | Merck Sharp & Dohme Corp. | Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment |
KR20140052018A (en) | 2011-08-09 | 2014-05-02 | 다케다 야쿠힌 고교 가부시키가이샤 | Cyclopropaneamine compound |
JP6215212B2 (en) | 2011-10-20 | 2017-10-18 | オリゾン・ジェノミックス・ソシエダッド・アノニマOryzon Genomics S.A. | (Hetero) arylcyclopropylamine compounds as LSD1 inhibitors |
BR112014009238B1 (en) | 2011-10-20 | 2022-08-09 | Oryzon Genomics S.A. | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS, THEIR USES AND PHARMACEUTICAL COMPOSITIONS |
JP6337255B2 (en) | 2012-07-27 | 2018-06-06 | ザ ブロード インスティテュート, インコーポレーテッドThe Broad Institute, Inc. | Inhibitors of histone deacetylase |
US9751885B2 (en) | 2012-10-12 | 2017-09-05 | Takeda Pharmaceutical Company Limited | Cyclopropanamine compound and use thereof |
EP2927212A4 (en) | 2012-11-28 | 2016-06-08 | Univ Kyoto | Lsd1-selective inhibitor having lysine structure |
EP2740474A1 (en) | 2012-12-05 | 2014-06-11 | Instituto Europeo di Oncologia S.r.l. | Cyclopropylamine derivatives useful as inhibitors of histone demethylases kdm1a |
WO2014164867A1 (en) | 2013-03-11 | 2014-10-09 | Imago Biosciences | Kdm1a inhibitors for the treatment of disease |
WO2014194280A2 (en) | 2013-05-30 | 2014-12-04 | The Board of Regents of the Nevada System of Higher Education on behalf of the University of | Novel suicidal lsd1 inhibitors targeting sox2-expressing cancer cells |
WO2015089192A1 (en) | 2013-12-11 | 2015-06-18 | Quanticel Pharmaceuticals, Inc. | Inhibitors of lysine specific demethylase-1 |
US9527835B2 (en) | 2014-02-13 | 2016-12-27 | Incyte Corporation | Cyclopropylamines as LSD1 inhibitors |
CN106488915B (en) | 2014-02-13 | 2020-10-02 | 因赛特公司 | Cyclopropylamines as LSD1 inhibitors |
EP3626713B1 (en) * | 2014-02-13 | 2021-09-29 | Incyte Corporation | Cyclopropylamines for use as lsd1 inhibitors |
EP3392244A1 (en) | 2014-02-13 | 2018-10-24 | Incyte Corporation | Cyclopropylamines as lsd1 inhibitors |
MY180575A (en) | 2014-04-11 | 2020-12-02 | Takeda Pharmaceuticals Co | Cyclopropanamine compound and use thereof |
EP3137169B1 (en) | 2014-05-01 | 2021-11-10 | Celgene Quanticel Research, Inc. | Inhibitors of lysine specific demethylase-1 |
AU2015311805B2 (en) | 2014-09-05 | 2020-04-02 | Celgene Quanticel Research, Inc. | Inhibitors of lysine specific demethylase-1 |
EP3250552B1 (en) | 2015-01-30 | 2019-03-27 | Genentech, Inc. | Therapeutic compounds and uses thereof |
WO2016130952A1 (en) | 2015-02-12 | 2016-08-18 | Imago Biosciences, Inc. | Kdm1a inhibitors for the treatment of disease |
AU2016243939B2 (en) | 2015-04-03 | 2020-09-03 | Incyte Holdings Corporation | Heterocyclic compounds as LSD1 inhibitors |
WO2017109061A1 (en) | 2015-12-23 | 2017-06-29 | Ieo - Istituto Europeo Di Oncologia S.R.L. | Spirocyclopropylamine derivatives useful as inhibitors of histone demethylases kdm1a |
-
2016
- 2016-11-03 CA CA3009805A patent/CA3009805C/en active Active
- 2016-11-03 MX MX2018008052A patent/MX2018008052A/en unknown
- 2016-11-03 EP EP16805585.3A patent/EP3397616B1/en active Active
- 2016-11-03 SG SG11201805645QA patent/SG11201805645QA/en unknown
- 2016-11-03 CN CN201680077382.5A patent/CN108884029B/en active Active
- 2016-11-03 WO PCT/US2016/060379 patent/WO2017116558A1/en active Application Filing
- 2016-11-03 AU AU2016382463A patent/AU2016382463B2/en active Active
- 2016-11-03 JP JP2018534842A patent/JP6916795B2/en active Active
- 2016-11-03 KR KR1020187021819A patent/KR20180117602A/en not_active Application Discontinuation
- 2016-11-03 US US15/343,008 patent/US9809541B2/en active Active
-
2017
- 2017-10-05 US US15/725,949 patent/US10233152B2/en active Active
-
2018
- 2018-06-22 IL IL260217A patent/IL260217B/en active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
CA3009805C (en) | 2023-10-17 |
KR20180117602A (en) | 2018-10-29 |
CA3009805A1 (en) | 2017-07-06 |
JP2019504059A (en) | 2019-02-14 |
IL260217A (en) | 2018-07-31 |
WO2017116558A1 (en) | 2017-07-06 |
US9809541B2 (en) | 2017-11-07 |
MX2018008052A (en) | 2019-03-14 |
CN108884029B (en) | 2021-10-26 |
CN108884029A (en) | 2018-11-23 |
US10233152B2 (en) | 2019-03-19 |
IL260217B (en) | 2020-09-30 |
AU2016382463B2 (en) | 2021-05-27 |
US20180127369A1 (en) | 2018-05-10 |
AU2016382463A1 (en) | 2018-07-12 |
EP3397616B1 (en) | 2020-06-10 |
JP6916795B2 (en) | 2021-08-11 |
EP3397616A1 (en) | 2018-11-07 |
US20170183308A1 (en) | 2017-06-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201805645QA (en) | Lsd1 inhibitors | |
SG11201805300QA (en) | Heterocyclic compounds as immunomodulators | |
SG11201810983PA (en) | Novel heterocyclic derivatives useful as shp2 inhibitors | |
SG11201906891RA (en) | Methods for the administration of certain vmat2 inhibitors | |
SG11201810171SA (en) | Kras g12c inhibitors | |
SG11201808682XA (en) | Silicone atoms containing ivacaftor analogues | |
SG11201803920TA (en) | Compounds and compositions useful for treating disorders related to ntrk | |
SG11201804934PA (en) | Novel Compounds | |
SG11201809299QA (en) | Formulations of an lsd1 inhibitor | |
SG11201907544VA (en) | Jak inhibitors containing a 4-membered heterocyclic amide | |
SG11201804170RA (en) | Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders | |
SG11201809714TA (en) | Piperidines as menin inhibitors | |
SG11201900163PA (en) | Macrocycle kinase inhibitors | |
SG11201408769QA (en) | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy | |
SG11201804309PA (en) | Antibody molecules to april and uses thereof | |
SG11201809751XA (en) | Egfr inhibitor compounds | |
SG11201906386XA (en) | Combination therapy involving diaryl macrocyclic compounds | |
SG11201408261UA (en) | Syringe | |
SG11201806583XA (en) | Compositions containing tucaresol or its analogs | |
SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
SG11201907889YA (en) | Glycan-interacting compounds and methods of use | |
SG11201900405XA (en) | Compounds, compositions and methods for treating or preventing a sympton associated with gout or hyperuricemia | |
SG11201900554YA (en) | Spiro-lactam nmda modulators and methods of using same | |
SG11201909837YA (en) | Methods for treating lung disorders | |
SG11201901438VA (en) | Solid forms of cenicriviroc mesylate and processes of making solid forms of cenicriviroc mesylate |